Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone (GnRH) Agonist Therapy for Prostate Cancer
- The study will be divided into 2 groups: one group (Cohort A) will consist of men
undergoing GnRH agonist therapy for at least 24 months. The second group (Cohort B)
will consist of men undergoing the same treatment but who are scheduled to receive only
6 months of treatment.
- The following tests and procedures will be performed when the participant joins the
study, then at 3, 6, 12 and 24 months thereafter. (All visits will take place at the
General Clinical Research Center (GCRC) at the Massachusetts General Hospital.) Height
and weight; blood and urine samples; Oral Glucose Tolerance Test (OGTT), Dual energy
X-ray Absorptiometry scan; medical history; and physical examinations.
Observational Model: Case-Only, Time Perspective: Prospective
Matthew R. Smith, MD, PhD
Massachusetts General Hospital
United States: Institutional Review Board
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|